Quarterly ResultMay 8, 2026, 09:12 AM
BioAge Labs Q1 Net Loss $(22.25)M; Raises $123.6M from Offering
AI Summary
BioAge Labs reported a net loss of $(22.25) million for Q1 2026, an increase from $(12.93) million in Q1 2025, primarily due to higher research and development expenses. Collaboration revenue increased to $2.77 million for the quarter. The company significantly strengthened its liquidity by raising $123.6 million in net proceeds from an underwritten public offering in January and February 2026, bringing total cash, cash equivalents, and marketable securities to $384.9 million as of March 31, 2026.
Key Highlights
- Net proceeds from January/February 2026 public offering totaled $123.6 million.
- Cash, cash equivalents, and marketable securities reached $384.9 million as of March 31, 2026.
- Q1 2026 net loss was $(22.25) million, up from $(12.93) million year-over-year.
- Collaboration revenue for Q1 2026 increased to $2.77 million from $1.45 million YoY.
- Research and development expenses rose to $20.41 million from $11.11 million YoY.
- Net loss per share for Q1 2026 was $(0.52), compared to $(0.36) in Q1 2025.
- The remaining term loan principal of $0.5 million was repaid in full on April 1, 2026.